Interactive Session:
197. Challenging Cases in ID
Saturday, October 5, 2013: 2:00 PM-3:30 PM
Room: The Moscone Center: Esplanade Ballroom 301-310

Learning Objectives:

It is assumed that participants know or are familiar with basic concepts in the recognition, pathogenesis, differential diagnosis, and management of infectious diseases. These skills will be challenged through a series of “unknown” case presentations in which the audience participants will be able to compare their case analyses to those of a panel of experts. At the conclusion of this session, participants, through observation and discussion, will be able to apply new skills in the approach to the analysis of infectious diseases syndromes as well as development of a differential diagnosis and a management approach for infectious diseases.  At the conclusion of this session, participants will be able to:

  • analyze infectious disease syndromes in a case study
  • select appropriate ID drug therapy in a given case scenerio

Target Audience: pharmacists, members-in-training, medical students and residents, infectious diseases physicians, clinicians, academicians

Tracks: Pediatric ID, Investigative ID, HIV-STD-TB, Global ID, Epidemiology and Infection Control, Adult ID

Interactive Moderators:  Henry Chambers, MD, FIDSA, University of California at San Francisco and Nesli Basgoz, MD, FIDSA, Massachusetts General Hospital

Presentations:

2:00 PM
Interactive Panelist
Lisa G. Winston, MD

2:20 PM
Interactive Panelist
Stanley Deresinski, MD, FIDSA

2:40 PM
Interactive Panelist
Wendy Armstrong, MD, FIDSA

3:00 PM
Interactive Panelist
Thomas G. Slama, MD, FIDSA

3:20 PM
Interactive Panelist
Stephen B. Calderwood, MD, FIDSA

CME Credits: Maximum of 1.5 hours of AMA PRA Category 1 CreditTM

ACPE Credits: ACPE 1.5 application-based contact hours (0.15 CEU) of pharmacy CE

ACPE Number: 0221-9999-13-127-L01-P

Disclosures:

H. Chambers, Astra Zeneca: Scientific Advisor, Consulting fee
Pfizer: Scientific Advisor, Consulting fee
Trius: Grant Investigator, Scientific Advisor and Stock Options, Consulting fee, Grant recipient and Stock Options
Theravance: Scientific Advisor, Consulting fee

N. Basgoz, None

L. G. Winston, None

S. Deresinski, None

W. Armstrong, None

T. G. Slama, None

S. B. Calderwood, None

See more of: Interactive Session

Findings in the abstracts are embargoed until 12:01 a.m. PST, Oct. 2nd with the exception of research findings presented at the IDWeek press conferences.